Faculty profile

Parneet Cheema

Back to faculty

Assistant ProfessorDepartment of MedicineUniversity of Toronto

Parneet Cheema

Assistant Professor

Department of Medicine

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
10 publications in the last five years, latest in 2026.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

284

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Targeting common EGFR mutations in non–small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors
Journal of the National Cancer Institute · 2026
Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study.
Cancer medicine · 2025
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC
Lung Cancer · 2025

All 16 publications

16 publications.

Targeting common EGFR mutations in non–small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors

Melosky B, Juergens RA, Chu QSC, Cheema P, Snow S, Leighl NB, Blais N, Ionescu DN, McLeod D, Tsao M-S

Journal of the National Cancer Institute20265 citations

DOI: 10.1093/jnci/djag008

Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study.

Liu G, Nyaw SF, Mok TSK, Curcio H, Cortot AB, Kam TY, Descourt R, Chik YK, Cheema P, Gwinnutt JM, Churchill EN, Nyborn J, Curran E, Savell A, Yin Y, Chong K, Tanaka-Chambers Y, Kretz J, Cadranel J

Cancer medicine20253 citationsOpen Access

DOI: 10.1002/cam4.70369 PMID: 39861957

Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC

Melosky B, Chu QSC, Juergens RA, Snow S, Blais N, Cheema P, Sangha R, Agulnik J, Martins I, Burkes RL

Lung Cancer20252 citations

DOI: 10.1016/j.lungcan.2025.108717

The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer

Melosky B, Juergens RA, Banerji S, Sacher A, Wheatley-Price P, Snow S, Tsao M-S, Leighl NB, Martins I, Cheema P

Therapeutic Advances in Medical Oncology20252 citationsOpen Access

DOI: 10.1177/17588359241308784

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.

Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price P, Shepherd FA, Florescu M, Cheema P, Chu QSC, Kim SW, Morgensztern D, Johnson ML, Cousin S, Kim DW, Moskovitz MT, Vicente D, Aronson B, Hobson R, Ambrose HJ, Khosla S, Reddy A, Russell DL, Keddar MR, Conway JP, Barrett JC, Dean E, Kumar R, Dressman M, Jewsbury PJ, Iyer S, Barry ST, Cosaert J, Heymach JV

Nature medicine2024132 citationsOpen Access

DOI: 10.1038/s41591-024-02808-y PMID: 38351187

Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer

Melosky B, Vincent MD, McGuire AL, Brade AM, Chu Q, Cheema P, Martins I, Spicer JD, Snow S, Juergens RA

International Journal of Cancer20245 citationsOpen Access

DOI: 10.1002/ijc.35031

Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective

Breadner D, Hwang DM, Husereau D, Cheema P, Doucette S, Ellis PM, Kassam S, Leighl N, Maziak DE, Selvarajah S

Current Oncology20245 citationsOpen Access

DOI: 10.3390/curroncol31100449

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.

Cheema P, Cho BC, Freitas H, Provencio M, Chen YM, Kim SW, Wu YL, Passaro A, Martin C, Tiseo M, Chang GC, Park K, Solomon B, Burghuber O, Laskin J, Wang Z, Lee SY, Hu Y, Vansteenkiste J, Zhang HL, Hanrahan E, Geldart T, Taylor R, Servidio L, Li J, Marinis F

Future oncology (London, England)2023First author

DOI: 10.2217/fon-2022-0919 PMID: 36656302

Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.

Verhoek A, Cheema P, Melosky B, Samson B, Shepherd FA, de Marinis F, John T, Wu YL, Heeg B, Van Dalfsen N, Bracke B, Miranda M, Shaw S, Moldaver D

PharmacoEconomics - open2023

DOI: 10.1007/s41669-023-00396-0 PMID: 36811822

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.

Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T

Nature medicine2022

DOI: 10.1038/s41591-022-01933-w PMID: 35995953

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Parneet Cheema

Research

Latest papers

Targeting common EGFR mutations in non–small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors

Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study.

Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC

The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.

Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer

Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.

Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.

Frequent collaborators

Rosalyn Juergens

Geoffrey Liu

Paul Wheatley-Price

Normand Blais

Adrian Sacher

Ming-Sound Tsao

Ming Tsao

Mark Vincent

Patrick Cheung

William Chu

Darby Erler

Hany Soliman

Yee Ung

Ian Poon

Natasha Leighl

Susanna Cheng

Kévin Jao

Suneil Khanna

David Hwang

Anand Swaminath

Arjun Sahgal

Devin Schellenberg

Glenwood Goss

Peter Ellis

Shantanu Banerji

Sunil Verma

Shamini Selvarajah